CTIS2024-514687-33-00进行中（未招募）1 期
Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL)
Ospedale San Raffaele S.r.l.0 个研究点目标入组 55 人开始时间: 2024年7月2日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Age =18 but <65 years, Active CLL/SLL requiring treatment according to iwCLL 2018 criteria, No previous CLL/SLL therapy, Appropriate medullary function: a. ANC =1.0 x 109/L; B. Plt =25 x 109/L; c. Hb =8.0 g/dl
排除标准
- •Previous treatment for CLL/SLL, Known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C (HCV). Subjects who are positive for HBcAb, HBsAb or the hepatitis C antibody should have a negative result of the polymerase chain reaction (PCR) prior to enlistment. Those who test positive for PCR will be excluded., Note hypersensitivity to one or more drugs in the study, Known hemorrhagic disorders (e.g. von Willebrand's disease) or haemophilia, History of stroke or intracranial bleeding in the 6 months prior to enlistment, Major surgery within 4 weeks of first dose of the drug in the study, Cardiovascular disease currently active and clinically significant such as uncontrolled arrhythmia or congestive heart failure of class 3 or 4 as defined by the functional classification of the New York Heart Association or a history of myocardial infarction, unstable angina, History of other malignant malignancies, except in situ carcinoma or malignant cancers treated with curative intent, Known story or suspected transformation of Richter, Hypersensitivity known to one or more drugs in the study, Inadequate kidney function: CrCl <30 ml/min, Autoimmune hemolytic anemia or uncontrolled autoimmune platelets, Need for warfarin or derivatives therapy, Treatment within 7 days before the first dose of the drug in the study with one of the following: a. Steroid therapy with antineoplastic intent B. Moderate or powerful cytochrome inhibitors P450 3A (CYP3A) (see Appendix G for examples) C. Moderate or strong CYP3A inducers (see Appendix G for examples), Administration or consumption of any of the following within 3 days before the first dose of the drug in the study: a. Pompelmo or grapefruit products B. Seville oranges (including jam containing Seville oranges) c. Carambola
研究者
相似试验
进行中（未招募）
1 期
Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemiaPreviously Untreated Chronic Lymphophatic LeukaemiaMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864EUCTR2020-004409-30-ITOSPEDALE SAN RAFFAELE55
进行中（未招募）
2 期
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaMantle Cell LymphomaNCT03710772M.D. Anderson Cancer Center51
招募中
2 期
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia (CLL)NCT04758975Paolo Ghia55
进行中（未招募）
1 期
Effect of treatment of patients with CLL/SLL with venetoclax and ibrutinib induction followed by ibrutinib and obinutuzumab in patients with residual diseaseMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2019-002528-34-NLHOVON Foundation85
进行中（未招募）
1 期
Effect of treatment of patients with CLL/SLL with venetoclax and ibrutinib induction followed by ibrutinib and obinutuzumab in patients with residual diseaseMedDRA version: 21.0Level: LLTClassification code 10009310Term: CLLSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2019-002528-34-DKHOVON Foundation85